XVARY Composite Score
/ 100
Combines growth, value, risk, and momentum factors into a single institutional-grade score.
Start here if you're new
What it is
Kestra makes a wearable device that can shock a patient’s heart and wraps it with monitoring, data, and support services.
How it gets paid
Last year Kestra Medical Tech made $60M in revenue.
Why it's growing
Revenue grew 115.1% last year. The $42M revenue print matters because it equals about 70% of the entire current $60M trailing 12-month revenue base.
What just happened
Revenue hit $42M, up 86% vs. prior year, while gross margin reached 48.3%.
At a Glance
N/a balance sheet
-$5.13 fy2024 eps est
$2B fy2026 rev est
N/a operating margin
~$1B market cap
What They Do
Kestra makes a wearable device that can shock a patient’s heart and wraps it with monitoring, data, and support services.
Kestra is selling one cardiac safety stack instead of a pile of vendors. If you are a hospital or cardiologist, one vendor is easier than stitching together monitoring, therapy, data, and support on your own. That simplicity helped revenue reach $60M, up 115.1% vs. prior year, while gross margin hit 48.3%.
How They Make Money
$60M
annual revenue · their business grew +115.1% last year
total revenue
$60M
+115.1%
The Products That Matter
Wearable defibrillator therapy
Assure wearable cardioverter defibrillator
$22.6M latest quarter · $60M annual revenue base
This is the business. The latest quarter printed $22.6M in revenue, and the company says market-share gains are driving the growth.
the revenue engine
Remote monitoring platform
cardiac recovery system platform
no separate revenue disclosed
It supports the WCD offering, but the company does not break out standalone sales. For you as a shareholder, that means the platform matters strategically more than financially right now.
supporting layer
Key Numbers
$2.0B
fy2026 revenue
The 2026 revenue forecast is 33 times the current $60M run rate. Plain English: the stock is priced for a rocket, not a ramp.
$138M
stock raise
Kestra sold 6,000,000 shares at $23 for about $138M gross. Plain English: the company bought time with cash and paid for it with dilution.
-177.8%
operating margin
Operating margin means profit after core business costs, and -177.8% means Kestra lost about $1.78 from operations for every $1 of sales.
$45M
long debt
Long-term debt is only 4% of capital. Plain English: leverage is not the main problem here. Losses are.
Financial Health
n/a
Strength
- balance sheet grade n/a
- long-term debt $45M (4% of capital)
n/a — functional but not a standout on the balance sheet.
Total Return vs. Market
source: institutional data · return history unavailable
What Just Happened
beat estimates
Revenue hit $42M, up 86% vs. prior year, while gross margin reached 48.3%.
Sales are scaling fast, but profits are still nowhere close. Quarterly EPS was -$1.14, and the full-year EPS estimate sits at -$5.13.
$42M
revenue
-$1.14
eps
48.3%
gross margin
the number that mattered
The $42M revenue print matters because it equals about 70% of the entire current $60M trailing 12-month revenue base.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. Plain English, no spam.
Weekly updates
Earnings alerts
Plain English
No spam
What Could Go Wrong
The biggest risk here is single-product execution in the wearable defibrillator market. KMTS gets its revenue from one commercial engine, and the valuation assumes that engine keeps accelerating.
Med
Single-product concentration
Assure appears to account for essentially all of the company’s $60M revenue base. If hospital adoption slows, reimbursement changes, or a competitor wins the account, there is no second segment large enough to offset it.
Revenue exposure: effectively the full reported business today.
Med
Premium multiple without profits
The stock trades at 16.7x sales while analysts still estimate a -$5.13 EPS figure. You are paying growth-stock prices for a company that has not yet shown earnings power.
If growth cools before margins improve, the multiple can compress fast.
Med
Gross margin may not scale fast enough
A 48.3% gross margin is respectable for a hardware-heavy medtech story, but it is not software money. The company still needs meaningfully more revenue to absorb selling, admin, and clinical support costs.
A margin plateau around current levels would delay the path to breakeven.
Med
Forecast credibility risk
This page includes a $2B fy2026 revenue estimate against a current annual revenue base of $60M and a latest quarter of $22.6M. That gap is so large it deserves skepticism, not blind acceptance.
When expectations get disconnected from the current base, even a good quarter can disappoint the stock.
At $24.82, you are buying a company worth about $1B with one revenue-generating product, a 48.3% gross margin, and losses still running through the income statement.
Source: institutional data · regulatory filings · risk analysis
Pay Attention To
Calendar
Q3 fy26 earnings on march 17, 2026
The last quarter printed $22.6M in revenue. The next report needs to show that growth was not a one-quarter spike.
Metric
Gross margin above 48.3%
Revenue growth gets the headlines. Margin tells you whether scale is actually making the model better.
Risk
Assure still carrying the entire story
As long as one product drives the business, every commercial stumble matters more than it would at a diversified medtech company.
Trend
Whether the stock can grow into the 16.7x sales multiple
At this valuation, good growth is expected. What moves the stock next is proof that growth can persist and losses can narrow at the same time.
Institutional Activity
institutional ownership data for KMTS is being compiled.
Source: institutional data
Price Targets
3-5 year target range
$25
Current price
Target midpoint · from current
Want the deeper analysis?
The full deep dive: DCF model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
See plans from $5/moThe Deep Dive